NCT01127594已完成1 期
A Multi-Center Phase I Dose Escalation Trial to Evaluate Safety and Tolerability of Intra-Arterial Temozolomide for Patients With Advanced Extremity Melanoma Using Normothermic Isolated Limb Infusion
Douglas Tyler6 个研究点 分布在 1 个国家目标入组 29 人开始时间: 2010年7月最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 29
- 试验地点
- 6
- 主要终点
- Safety Profile of intra-arterial temozolomide and maximum tolerated dose of temozolomide
研究概览
简要总结
The purpose of this study is to determine the safety profile of intra-arterial temozolomide administration during Isolated Limb Infusion (ILI) by defining the dose limiting toxicities associated with this treatment. This study also aims to determine the maximum tolerated dose of intra-arterial administration of temozolomide during ILI that will be used in a phase II trial.
详细描述
- The primary objective of this study is to determine the safety profile of intra-arterial temozolomide administration during Isolated Limb Infusion (ILI) by defining the dose limiting toxicities associated with this treatment and to determine the maximum tolerated dose of intra-arterial administration of temozolomide during ILI that will be used in a phase II efficacy trial.
- Population will include patients who have undergone a previous Melphalan based regional therapy for which they did not respond optimally and present with persistent, progressive, or recurrent disease. Study activities include tumor tissue sampling, blood sampling, and subjects will undergo an Isolated Limb Infusion.
- To define both response in-field (area of the limb below the tourniquet) and out-of-field (any area outside the tourniquet) in patients treated with temozolomide based ILI. Response in this trial will be defined by the RECIST criteria (CR, PR, SD, PD at 12 weeks post ILI). A CR rate of 20% would be considered as preliminary evidence of a promising approach in this group of patients that have had a previous melphalan regional treatment. ILI with melphalan has a complete response rate of approximately 35% in naïve patients and 20% in patients who have previously received melphalan based regional therapy.
To assess if the proposed treatment has any effect on quality of life as measured by the Functional Assessment of Cancer Therapy - Melanoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient must have undergone a previous Melphalan based regional therapy for which they did not respond optimally and present with persistent, progressive, or recurrent disease.
- •Patient must be 18 years of age or older.
- •Patient must have an ECOG status of 0-
- •Patient must have histologically proven primary or recurrent extremity melanoma, stage IIIB, IIIC, or IV
- •Patients with Stage IIIC disease must either have had regional lymph nodes previously removed or will have them removed at the time of regional treatment.
- •Patients with Stage IV disease must have had all distant disease resected at least 30 days prior to regional treatment.
- •Disease to be treated by ILI must be distal to the planned site of tourniquet placement
- •Patient's disease must be bi-dimensionally measurable by caliper or radiological method as defined in the RECIST criteria.
- •Patient must have adequate bone marrow, liver and renal function
- •Patient must have a palpable femoral/radial pulse in the affected extremity.
- •Recovery from relevant toxicity prior to first study drug administration.
- •Patients must have a life expectancy of > 6 months.
- •Ability to read and understand English and the ability to complete paper +/- electronic survey assessments.
排除标准
- •Cardiac disease: Congestive heart failure > class II NYHA.
- •Known brain metastasis.
- •Uncontrolled hypertension defined as systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg, despite optimal medical management.
- •Known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C.
- •Active clinically serious infection > CTCAE Grade
- •Thrombotic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months.
- •Pulmonary hemorrhage/bleeding event > CTCAE Grade 2 within 4 weeks of administration of TMZ
- •Any other hemorrhage/bleeding event > CTCAE Grade 3 within 4 weeks of administration of TMZ.
- •Serious non-healing wound, ulcer, or bone fracture.
- •Major surgery or significant traumatic injury within 30 days of ILI.
- •Evidence or history of bleeding diathesis or coagulopathy.
- •Antineoplastic therapy, radiotherapy, or any other investigational drug within 30 days prior to first study drug administration.
- •Patients with symptoms or signs of vascular insufficiency. Specifically, patients with any history of blood clots or lifestyle altering ischemic peripheral vascular disease will be excluded.
- •History of allergic reactions and/or hypersensitivity to TMZ.
- •Psychiatric conditions or diminished capacity that could compromise the giving of informed consent, or interfere with study compliance.
- •Pregnant or nursing women are not eligible for this study. Patients of reproductive potential must agree to use an effective method of birth control when undergoing treatments with known or possible mutagenic or teratogenic effects. All female participants of child-bearing potential must have a negative serum pregnancy test within two weeks of patient registration. Please note: use of contraception, including surgical procedures such as vasectomy or tubal ligation DO NOT eliminate the need for administering pregnancy testing.
- •Current treatment, or treatment in the previous 24 months, for another non-melanoma malignancy.
- •Unable to return at the regular required intervals for reassessment, or study drug administration.
- •Patients with known heparin induced thrombocytopenia.
结局指标
主要结局
Safety Profile of intra-arterial temozolomide and maximum tolerated dose of temozolomide
时间窗: 12 Weeks
To determine the safety profile of intra-arterial temozolomide administration during Isolated Limb Infusion (ILI) by defining the dose limiting (DLT) and non dose limiting toxicities associated with this treatment. To determine the maximum tolerated dose (MTD) for intra-arterial administration of temozolomide during ILI that will be used in a phase II efficacy trial.
次要结局
- To define tumor response in field in patients treated with temozolomide(Until disease progression or death)
研究者
Douglas Tyler
Professor of Surgical Oncology
Duke University
研究点 (6)
Loading locations...
相似试验
终止
1 期
Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) MalignancyCentral Nervous System NeoplasmsNeoplasm MetastasisNCT00629187Tufts Medical Center2
Unknown
2 期
Temozolomide vs. Temozolomide and Thalidomide Treatment in Recurrent GlioblastomaGlioblastomaNCT00521482University of Zurich40
已完成
3 期
Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644)GlioblastomaAstrocytomaNCT00335075Merck Sharp & Dohme LLC151
终止
1 期
DepoCyt Plus Temozolomide in Patients With Neoplastic MeningitisNeoplastic MeningitisNCT00515788M.D. Anderson Cancer Center11
已完成
1 期
Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal CancerKRAS Mutant Metastatic Colorectal CancerNCT01274624Oncolytics Biotech36